Boston Scientific Co. (NYSE:BSX) Shares Purchased by Angeles Wealth Management LLC

Angeles Wealth Management LLC boosted its holdings in Boston Scientific Co. (NYSE:BSX) by 14.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,366 shares of the medical equipment provider’s stock after buying an additional 415 shares during the quarter. Angeles Wealth Management LLC’s holdings in Boston Scientific were worth $301,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BSX. Compagnie Lombard Odier SCmA increased its holdings in shares of Boston Scientific by 280.4% in the 3rd quarter. Compagnie Lombard Odier SCmA now owns 3,100 shares of the medical equipment provider’s stock valued at $260,000 after acquiring an additional 2,285 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its stake in Boston Scientific by 32.4% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 3,786 shares of the medical equipment provider’s stock valued at $317,000 after purchasing an additional 927 shares during the last quarter. Paladin Wealth LLC acquired a new stake in Boston Scientific during the third quarter worth approximately $586,000. ORG Wealth Partners LLC purchased a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $89,000. Finally, Grove Bank & Trust boosted its holdings in shares of Boston Scientific by 12.9% in the 3rd quarter. Grove Bank & Trust now owns 2,801 shares of the medical equipment provider’s stock valued at $235,000 after buying an additional 320 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares in the company, valued at $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now owns 29,308 shares in the company, valued at $2,660,580.24. This represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 53,830 shares of company stock worth $5,149,969. Company insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on BSX shares. Bank of America lifted their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. StockNews.com raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, January 29th. Sanford C. Bernstein lifted their price target on Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Royal Bank of Canada increased their price objective on Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Finally, TD Cowen lifted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, December 12th. One investment analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $107.39.

Boston Scientific Trading Up 0.9 %

Shares of BSX stock opened at $106.15 on Tuesday. The business’s fifty day moving average price is $94.88 and its 200 day moving average price is $87.28. The firm has a market capitalization of $156.44 billion, a PE ratio of 84.92, a P/E/G ratio of 2.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a 1-year low of $64.54 and a 1-year high of $107.17.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.